Discontinued — last reported Q4 '22
Products & Services · Expense reflected within statements of income
Aducanumab — Expense reflected within statements of income
Biogen Aducanumab — Expense reflected within statements of income remained flat by 0.0% to $20.55M in Q4 2022 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalLower is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ4 2022Feb 14, 2024
How to read this metric
An increase indicates a higher direct impact on the company's operating expenses, potentially reducing net margins, while a decrease suggests lower net financial exposure to the collaboration.
Detailed definition
This metric represents the net portion of collaboration-related expenses that are recognized as operating expenses on th...
Peer comparison
Comparable to net operating expenses or net collaboration charges reported by peers in co-development or co-marketing pharmaceutical agreements.
Metric ID:
biib_segment_aducanumab_expense_reflected_within_statements_of_incomeHistorical Data
4 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | |
|---|---|---|---|---|
| Value | $20.55M | $20.55M | $20.55M | $20.55M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% |
Range$20.55M – $20.55M
Current Streak3+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's aducanumab — expense reflected within statements of income?
- Biogen (BIIB) reported aducanumab — expense reflected within statements of income of $20.55M in Q4 2022.
- What does aducanumab — expense reflected within statements of income mean?
- The net portion of partnership-related expenses that directly reduces the company's reported operating income.